PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

[1]  S. Oudard,et al.  Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.

[2]  D. Amadori,et al.  Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. , 2014, Endocrine-related cancer.

[3]  I. Tannock,et al.  Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment. , 2014, European urology.

[5]  X. Yao,et al.  Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.

[6]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[7]  F. Saad,et al.  Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. , 2013 .

[8]  S. Mundle,et al.  Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role. , 2013, Critical reviews in oncology/hematology.

[9]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[10]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[11]  D. Amadori,et al.  Perspectives on mTOR inhibitors for castration-refractory prostate cancer. , 2012, Current cancer drug targets.

[12]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[13]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[14]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. , 2009, European urology.

[15]  C. Sternberg,et al.  Prostate‐specific antigen flare phenomenon with docetaxel‐based chemotherapy in patients with androgen‐independent prostate cancer , 2008, BJU international.

[16]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Pond,et al.  Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study , 2008, Clinical Cancer Research.

[18]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Olbert,et al.  Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel , 2006, Anti-cancer drugs.

[20]  Tomasz Burzykowski,et al.  Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[22]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[23]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[24]  C. Mahler.  Is disease flare a problem? , 1993, Cancer.

[25]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[26]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[27]  T. Klatte,et al.  Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy , 2007, International Urology and Nephrology.

[28]  D. Gillatt,et al.  Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study , 2005, Prostate Cancer and Prostatic Diseases.